


TRIM24/BRPF1-IN-2

Cat. No.:	HY-143332
Molecular Formula:	C ₂₀ H ₂₂ N ₂ O ₄ S
Molecular Weight:	386.46
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TRIM24/BRPF1-IN-2 (compound 20l) is a potent TRIM24/BRPF1 dual inhibitor, with IC ₅₀ values of 0.98 and 1.16 μM, respectively. TRIM24/BRPF1-IN-2 shows TRIM24/BRPF1 bromodomain binding affinity. TRIM24/BRPF1-IN-2 can be used for prostate cancer research ^[1] .								
IC₅₀ & Target	BRPF1 1.16 μM (IC ₅₀)								
In Vitro	<p>TRIM24/BRPF1-IN-2 (compound 20l) (0-10 μM, 48 h) suppresses the growth of the prostate cell lines (C4-2B, LNCaP, and 22Rv1), with IC₅₀ values of 0.78±0.15, 1.07±0.47, and 0.82±0.26 μM, respectively^[1].</p> <p>TRIM24/BRPF1-IN-2 inhibits gene and protein expression in prostate cancer cells^[1].</p> <p>TRIM24/BRPF1-IN-2 displays reasonable Caco-2 permeability^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>RT-PCR^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>22Rv1 cell, LNCaP cells</td> </tr> <tr> <td>Concentration:</td> <td>0.4, 2, 5, and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the mRNA expression of full-length AR, AR-V7 and AR-regulated genes PSA, KLK2 and TMPRSS2. inhibited the mRNA level of C-MYC.</td> </tr> </table>	Cell Line:	22Rv1 cell, LNCaP cells	Concentration:	0.4, 2, 5, and 10 μM	Incubation Time:	48 h	Result:	Decreased the mRNA expression of full-length AR, AR-V7 and AR-regulated genes PSA, KLK2 and TMPRSS2. inhibited the mRNA level of C-MYC.
Cell Line:	22Rv1 cell, LNCaP cells								
Concentration:	0.4, 2, 5, and 10 μM								
Incubation Time:	48 h								
Result:	Decreased the mRNA expression of full-length AR, AR-V7 and AR-regulated genes PSA, KLK2 and TMPRSS2. inhibited the mRNA level of C-MYC.								
In Vivo	<p>TRIM24/BRPF1-IN-2 (compound 20l) (50 mg/kg, IP, once daily for 21 days) suppresses tumor growth (TGI = 53%) without exhibiting noticeable toxicity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mice (n = 5-7 per dose group, Four-week-old, male, non-obese diabetic server combined immune-deficiency (NOD SCID), 22Rv1 xenograft model)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP, once daily for 21 days</td> </tr> </table>	Animal Model:	Mice (n = 5-7 per dose group, Four-week-old, male, non-obese diabetic server combined immune-deficiency (NOD SCID), 22Rv1 xenograft model) ^[1]	Dosage:	50 mg/kg	Administration:	IP, once daily for 21 days		
Animal Model:	Mice (n = 5-7 per dose group, Four-week-old, male, non-obese diabetic server combined immune-deficiency (NOD SCID), 22Rv1 xenograft model) ^[1]								
Dosage:	50 mg/kg								
Administration:	IP, once daily for 21 days								

Result:	Inhibited the progression of the tumors significantly (53% tumor growth inhibition) without body weight loss.
---------	---

REFERENCES

[1]. Xiang Q, et al. Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors. Eur J Med Chem. 2022 Jun 5;236:114311.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA